coya 302
Generic: low-dose interleukin-2 and CTLA4-Ig·Code: COYA 302
coya 302: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Coya Therapeutics, Inc. (COYA) | Phase 2 |
FDA Decisions
FDA_MeetingFDA accepted Coya's IND to initiate the Phase 2 randomized, double-blind, placebo-controlled study of COYA 302 for ALS.(COYA)
Frequently asked questions
Who is developing coya 302?
coya 302 is being developed by Coya Therapeutics, Inc..
What is coya 302's latest FDA decision?
The most recent tracked FDA decision for coya 302 is FDA_Meeting for FDA accepted Coya's IND to initiate the Phase 2 randomized, double-blind, placebo-controlled study of COYA 302 for ALS..
Get deeper analysis on coya 302
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis